



Giulio C Spagnoli

Kontakt

Giulio C Spagnoli

Publikationen (19)

Nebiker C, Oertli D, von Holzen U, Adamina M, Muraro M, Mengus C, Zajac P, Sconocchia G, Zuber M, Tornillo L, Terracciano L, Bolli M, Rosso R, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser R, Spagnoli G. GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer. *Clin Cancer Res* 2014; 20:3094-106.

Adamina M, Spagnoli G, Marti W, Oertli D, Heberer M, Jacob A, Huegli R, Bolli M, Viehl C, Frey D, Weber W, Rosenthal R, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. *Mol Ther* 2010; 18:651-9.

Rosenthal R, Heberer M, Oertli D, von Holzen U, Frey D, Weber W, Bolli M, Iezzi G, Zajac P, Feder-Mengus C, Adamina M, Bracci L, Groeper C, Spagnoli G. Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. *J Immunother* 2009; 32:252-61.

Bracci L, Belardelli F, Proietti E, Iezzi G, Zajac P, Groeper C, Rosenthal R, Adamina M, Provenzano M, Schumacher R, Spagnoli G. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering. *J Immunother* 2008; 31:466-74.

Rosenthal R, Viehl C, Gueller U, Weber W, Adamina M, Spagnoli G, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. *J Am Coll Surg* 2008; 207:95-105.

Adamina M, Heberer M, Zuber M, Oertli D, Frey D, Gueller U, Zajac P, Schumacher R, Rosenthal R, Weber W, Spagnoli G. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. *Contemp Clin Trials* 2007; 29:165-81.

Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski H, Heberer M, Spagnoli G. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. *Int J Cancer* 2007; 120:337-43.

Adamina M, Guller U, Bracci L, Heberer M, Spagnoli G, Schumacher R. Clinical applications of virosomes in cancer immunotherapy. *Expert Opin Biol Ther* 2006; 6:1113-21.

Cavazza A, Marini M, Spagnoli G, Adamina M, Roda L. Permeability of phospholipid vesicles to the tumor antigen epitope gp100(280-288). *ChemMedChem* 2006; 1:816-20.

Adamina M, Oertli D, Spagnoli G, Amacker M, Zurbriggen R, Feder C, Groeper C, Rosenthal R, Weber W, Zajac P, Schumacher R, Heberer M. Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. *J Liposome Res* 2006; 16:195-204.

Schumacher R, Amacker M, Neuhaus D, Rosenthal R, Groeper C, Heberer M, Spagnoli G, Zurbriggen R, Adamina M. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. *Vaccine* 2005; 23:5572-82.

Bolli M, Spagnoli G, Hudolin T, Terracciano L, Carafa V, Sanguedolce F, Feder C, Gueller U, Zajac P, Schultz-Thater E, Tornillo L. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. *Int J Cancer* 2005; 115:960-6.

von Holzen U, Heberer M, Oertli D, Marti W, Schumacher R, Feder C, Reschner A, Groeper C, Zajac P, Weber W, Bolli M, Adamina M, Spagnoli G. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy. *Int J Cancer* 2005; 115:248-55.

Spagnoli G, Adamina M, Bolli M, Weber W, Zajac P, Marti W, Oertli D, Heberer M, Harder F. Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. *World J Surg* 2005; 29:692-9.

Cavazza A, Adamina M, Ausiello C, Giardina B, Marini M, Palazzo R, Roda L, Spagnoli G. Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. *Clin Immunol* 2004; 111:252-61.

Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, Heberer M, Spagnoli G. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. *Vaccine* 2004; 22:714-23.

Bolli M, Sauter G, Heberer M, Harder F, Gambazzi F, Mirlacher M, Haas P, Dalquen P, Guller U, Adamina M, Kocher T, Spagnoli G. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. *Ann Surg* 2002; 236:785-93; discussion 793.

Oertli D, Heberer M, Harder F, Schumacher R, Adamina M, Padovan E, Kocher T, Noppen C, Zajac P, Marti W, Spagnoli G. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. *Hum Gene Ther* 2002; 13:569-75.

Spagnoli G, Zajac P, Marti W, Oertli D, Padovan E, Noppen C, Kocher T, Adamina M, Heberer M. Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy. *Recent Results Cancer Res* 2002; 160:195-201.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch